Caliber Imaging & Diagnostics, Inc. (LCDX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Caliber Imaging & Diagnostics, Inc. (LCDX) trades at $0.00 with AI Score 57/100 (Grade B). Caliber Imaging & Diagnostics, Inc. is a U. S. Market cap: $5,104, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for LCDX: LCDX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LCDX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LCDX: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Caliber Imaging & Diagnostics, Inc. (LCDX) Healthcare & Pipeline Overview
Caliber Imaging & Diagnostics, Inc. is a U.S.-based medical technology firm specializing in advanced imaging solutions for cellular-resolution tissue visualization. The company develops, manufactures, and markets systems like VivaScope 1500 and VivaScope 3000, alongside VivaScan software and VivaNet telepathology, serving medical practitioners and scientists in diagnostic applications.
What Is the Investment Thesis for LCDX?
Caliber Imaging & Diagnostics, Inc. operates in the medical device sector, leveraging its advanced imaging solutions for cellular-resolution tissue visualization as a core value driver. The company's product suite, including the VivaScope 1500, VivaScope 3000, VivaScan, and VivaNet, addresses a specific need for high-fidelity, non-invasive diagnostics. However, the company faces significant financial challenges, evidenced by a negative profit margin of -164.0% and a market capitalization of 5K, indicating a micro-cap status and substantial unprofitability. Its beta of 0.45 suggests lower volatility relative to the broader market, yet this must be weighed against its operational and financial profile. As an 'OTC Other' listed stock, LCDX carries inherent risks of limited liquidity and regulatory oversight, requiring investors to closely monitor its ability to secure funding and navigate the complex medical device regulatory landscape. Potential growth catalysts include increased adoption of its specialized imaging technology, expansion into new diagnostic applications, and successful strategic partnerships to bolster its market presence and financial stability.
Based on FMP financials and quantitative analysis
LCDX Key Highlights
- Market Capitalization: $0.00B, reflecting a micro-cap status and extremely limited valuation.
- Profit Margin: -164.0%, indicating significant operational losses relative to revenue.
- Gross Margin: 19.6%, suggesting challenges in cost of goods sold relative to its pricing strategy.
- Beta: 0.45, indicating lower price volatility compared to the overall market.
- Employee Count: 28 employees, highlighting a relatively small operational scale for a medical technology firm.
Who Are LCDX's Competitors?
LCDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LCDX's Key Strengths?
- Proprietary advanced imaging technology for cellular-resolution tissue visualization.
- Specialized product portfolio including VivaScope 1500, VivaScope 3000, VivaScan, and VivaNet.
- Established operational history since 1991 in the medical technology sector.
- Focus on non-invasive diagnostic tools for living tissue.
What Are LCDX's Weaknesses?
- Significant unprofitability with a -164.0% profit margin.
- Limited market capitalization ($0.00B) indicating micro-cap status.
- Small operational scale with only 28 employees.
- OTC Other listing, implying limited liquidity and disclosure requirements.
What Could Drive LCDX Stock Higher?
- Potential regulatory approvals for new or enhanced imaging device applications.
- Successful securing of new funding or strategic partnerships to support R&D and market expansion.
- Increased adoption of VivaScope systems and associated software by medical practitioners and research institutions.
- Development and commercialization of next-generation cellular-resolution imaging technologies.
- Publication of clinical study results demonstrating the efficacy and utility of their diagnostic solutions.
What Are the Key Risks for LCDX?
- Financial-distress signal — its Altman Z-Score of -44.20 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Significant financial losses and negative profit margin (-164.0%), posing sustainability challenges.
- Limited liquidity and transparency due to its 'OTC Other' listing and small market capitalization.
- Inability to secure sufficient funding for continued research, development, and market penetration.
- Intense competition from larger, well-capitalized medical device companies with broader product portfolios.
- Regulatory hurdles and the need for continuous compliance in the evolving medical device landscape.
What Are the Growth Opportunities for LCDX?
- Expansion of Diagnostic Applications: The core technology of cellular-resolution imaging, exemplified by VivaScope 1500, has potential beyond current uses. Expanding its application to new medical fields such as oncology, pathology, or ophthalmology could significantly broaden the addressable market. The global medical imaging market is projected to grow, driven by increasing prevalence of chronic diseases and demand for early diagnosis. Developing clinical evidence for new indications could unlock substantial market segments, potentially attracting new partnerships and increasing device adoption over a 3-5 year horizon, thereby diversifying revenue streams and reducing reliance on existing applications.
- Geographic Market Penetration: Currently operating as a U.S.-based firm, Caliber Imaging & Diagnostics has an opportunity to expand its market reach internationally. Many developed and emerging markets are investing heavily in advanced healthcare infrastructure and diagnostic capabilities, presenting untapped demand. Establishing distribution networks or strategic alliances in key European or Asian markets could tap into new revenue streams. This expansion would require navigating diverse regulatory environments and market access strategies, with a potential timeline of 2-4 years for initial market entry and scaling, which could significantly increase the company's customer base and sales volume.
- Software and AI Integration: The VivaScan and VivaNet software platforms offer a foundation for enhanced diagnostic workflows. Integrating advanced artificial intelligence (AI) and machine learning (ML) algorithms for automated image analysis, disease detection, and predictive analytics could significantly improve diagnostic accuracy and efficiency. This would add substantial value to their existing hardware, creating a more comprehensive solution and potentially new recurring revenue streams through software subscriptions or enhanced service offerings. This technological enhancement could be a continuous development over the next 1-3 years, strengthening the company's competitive moat and improving diagnostic outcomes.
- New Product Development & Miniaturization: Continued innovation in imaging technology, including the development of next-generation VivaScope devices or more compact, portable solutions, represents a significant growth avenue. Miniaturization could enable point-of-care diagnostics in diverse settings, expanding accessibility beyond specialized clinics and hospitals. Investing in research and development to enhance resolution, speed, or non-invasiveness of their systems would maintain a competitive edge and open up new market segments. This ongoing innovation cycle is critical for long-term growth, with new product cycles typically spanning 3-5 years, ensuring the company remains at the forefront of medical imaging technology.
- Strategic Partnerships and Collaborations: Forming strategic alliances with larger medical device manufacturers, pharmaceutical companies, or research institutions could accelerate market adoption and product development. These partnerships could provide access to broader distribution channels, co-development opportunities for integrated diagnostic-therapeutic solutions, or funding for clinical trials. Collaborations could also help validate new applications for their technology, leveraging the expertise and resources of established players in the healthcare ecosystem. Such alliances could significantly de-risk market entry for new products or geographies, with potential impacts emerging within 1-2 years, providing a pathway to scale operations and expand market reach.
What Opportunities Does LCDX Have?
- Expansion into new diagnostic applications beyond current uses (e.g., oncology, pathology).
- Geographic market expansion beyond the U.S.
- Integration of AI/ML for enhanced image analysis and diagnostic capabilities.
- Development of next-generation or miniaturized imaging devices.
What Threats Does LCDX Face?
- Intense competition from larger, better-funded medical imaging companies.
- Regulatory hurdles and lengthy approval processes for medical devices.
- Challenges in securing adequate funding for R&D and market expansion.
- Risk of technological obsolescence from rapidly evolving imaging modalities.
What Are LCDX's Competitive Advantages?
- Proprietary cellular-resolution imaging technology, specifically reflectance confocal microscopy, for in vivo tissue visualization.
- Specialized product suite tailored for precise diagnostic applications in living tissue, offering unique capabilities.
- Integrated hardware and software ecosystem (VivaScope, VivaScan, VivaNet) providing a comprehensive solution.
- Established operational history since 1991, indicating deep expertise and experience in advanced medical imaging.
What Does LCDX Do?
Caliber Imaging & Diagnostics, Inc. is a U.S.-based medical technology firm dedicated to the development, manufacturing, and marketing of advanced imaging solutions that enable the visualization of living tissue at a cellular resolution. The company was initially established in 1991 under the name Lucid, Inc., marking its entry into the medical imaging landscape. Over two decades later, in August 2012, the company underwent a rebranding to its current identity, Caliber Imaging & Diagnostics, Inc., and maintains its headquarters in Andover, Massachusetts. Its core product portfolio is designed to empower medical practitioners and scientists with high-fidelity diagnostic tools. Central to its offerings is the VivaScope 1500, a sophisticated reflectance confocal imaging system. This device allows for the capture of detailed confocal images, providing an unprecedented view into the cellular architecture of living tissue, which is crucial for precise diagnostics and research. Complementing this stationary system, the company also provides the VivaScope 3000, a handheld in vivo reflectance confocal microscope specifically tailored for dermatological imaging. This portable solution offers flexibility and convenience for skin examinations, enabling on-the-spot cellular-level analysis. Beyond hardware, Caliber Imaging & Diagnostics extends its capabilities through specialized software. VivaScan is designed to streamline various operational aspects, including patient scheduling, facilitating multi-lesion imaging during appointments, and assisting with comprehensive image review and reporting. Furthermore, the firm supplies VivaNet, a sophisticated digital telepathology system that supports remote diagnostic capabilities, enhancing collaboration and access to expert analysis. The company's focus on non-invasive, high-resolution imaging positions it within the innovative segment of the medical device sector, addressing critical diagnostic needs.
What Products and Services Does LCDX Offer?
- Develops advanced imaging solutions for cellular-resolution tissue visualization.
- Manufactures the VivaScope 1500, a reflectance confocal imaging system for detailed cellular architecture.
- Markets the VivaScope 3000, a handheld in vivo reflectance confocal microscope tailored for dermatological imaging.
- Provides VivaScan software for streamlined patient scheduling, multi-lesion imaging, and image review and reporting.
- Offers VivaNet, a sophisticated digital telepathology system for remote diagnostic capabilities.
- Enables medical practitioners and scientists to capture detailed confocal images of living tissue.
- Focuses on non-invasive diagnostic tools within the medical device sector.
How Does LCDX Make Money?
- Sells advanced imaging hardware, including the VivaScope 1500 and VivaScope 3000, to medical facilities and research institutions.
- Generates revenue from software licenses and subscriptions for its VivaScan and VivaNet platforms.
- Provides ongoing maintenance, service, and technical support for its installed base of imaging systems.
- Potentially derives revenue from specialized accessories or consumables related to its imaging platforms.
What Industry Does LCDX Operate In?
Caliber Imaging & Diagnostics, Inc. is positioned within the dynamic medical device sector, specifically focusing on advanced diagnostic imaging technologies. The industry is characterized by a continuous drive towards non-invasive, high-resolution imaging solutions that enable earlier and more accurate disease detection. Market trends indicate a growing demand for specialized imaging tools, particularly in areas like dermatology and pathology, where cellular-level detail is paramount. LCDX differentiates itself by specializing in reflectance confocal imaging, providing cellular-resolution visualization of living tissue, which sets it apart from broader imaging modalities. The competitive landscape includes both large, diversified medical technology companies and smaller, innovative firms focused on niche imaging solutions. Caliber Imaging & Diagnostics aims to carve out its market share by offering highly specialized hardware and integrated software solutions that cater to the precise diagnostic needs of medical practitioners and scientists.
Who Are LCDX's Key Customers?
- Medical practitioners, including dermatologists and pathologists, seeking advanced diagnostic tools.
- Scientists and researchers in academic, pharmaceutical, and private institutions utilizing cellular imaging.
- Hospitals and specialized clinics requiring high-resolution, non-invasive diagnostic capabilities.
- Telemedicine providers and pathology labs leveraging digital telepathology systems.
Net buyingInsider Activity
The most recent 11 insider filings for Caliber Imaging & Diagnostics, Inc. break down as 2 sales and 9 purchases. On net that is roughly 265K shares acquired (about $1.0M) — insiders putting money in tends to read as conviction.
LCDX Valuation & Market Position
With a 5K market cap, Caliber Imaging & Diagnostics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, LCDX's quantitative score of 57/100 is below the peer average of 69/100.
ROE 54%Key Financial Metrics
Return on equity for Caliber Imaging & Diagnostics, Inc. stands at 54.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.31 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 1/9Financial Health
Caliber Imaging & Diagnostics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -44.20 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Caliber Imaging & Diagnostics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Andover, US. The company is led by CEO L. Michael Hone. LCDX has traded publicly since 2012.
LCDX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary advanced imaging technology for cellular-resolution tissue visualization.
- Specialized product portfolio including VivaScope 1500, VivaScope 3000, VivaScan, and VivaNet.
- Established operational history since 1991 in the medical technology sector.
- Focus on non-invasive diagnostic tools for living tissue.
Bear Case
- Significant unprofitability with a -164.0% profit margin.
- Limited market capitalization ($0.00B) indicating micro-cap status.
- Small operational scale with only 28 employees.
- OTC Other listing, implying limited liquidity and disclosure requirements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
LCDX Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
LCDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LCDX.
Price Targets
Wall Street price target analysis for LCDX.
LCDX MoonshotScore
What does this score mean?
The MoonshotScore rates LCDX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: L. Michael Hone
Chief Executive Officer
L. Michael Hone serves as the Chief Executive Officer of Caliber Imaging & Diagnostics, Inc., overseeing its operations and strategic direction. With a focus on advancing medical technology, Mr. Hone is responsible for managing the company's 28 employees and guiding its efforts in developing, manufacturing, and marketing advanced imaging solutions. His leadership is central to the company's mission of providing cellular-resolution tissue visualization tools to medical practitioners and scientists. Specific details regarding his prior career history, education, and other roles are not provided in the available data.
Track Record: Under Mr. Hone's leadership, Caliber Imaging & Diagnostics, Inc. continues to focus on its core product lines, including the VivaScope 1500, VivaScope 3000, VivaScan, and VivaNet systems. His tenure has seen the company maintain its specialization in reflectance confocal imaging for diagnostic applications. Key achievements and strategic decisions beyond these operational continuities are not detailed in the provided information.
LCDX OTC Market Information
Caliber Imaging & Diagnostics, Inc. trades on the 'OTC Other' tier of the OTC Markets. This tier is for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide current information. Unlike exchanges such as the NYSE or NASDAQ, which have stringent listing standards for financial health, corporate governance, and minimum share prices, 'OTC Other' has minimal requirements. This often results in less transparency and higher risk for investors compared to exchange-listed or even higher-tier OTC stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency due to 'OTC Other' classification.
- Extremely low trading volume and wide bid-ask spreads, leading to illiquidity.
- Difficulty in securing capital and attracting institutional investment.
- Increased susceptibility to market manipulation and price volatility.
- Potential for delisting or further restrictions if disclosure status remains 'Unknown'.
- Verify any available financial statements and corporate filings directly from the company or OTC Markets.
- Research the company's operational status, product sales, and customer base beyond public filings.
- Assess the competitive landscape and the company's market position within the medical device sector.
- Investigate any recent news, press releases, or investor relations updates from the company.
- Evaluate the management team's experience and track record, seeking information beyond basic profiles.
- Understand the regulatory environment for their medical devices and any pending approvals.
- Consider the potential for dilution from future capital raises.
- Established company history, founded as Lucid, Inc. in 1991.
- Specific product lines (VivaScope 1500, VivaScope 3000, VivaScan, VivaNet) with defined applications.
- Headquartered in Andover, Massachusetts, indicating a physical operational base.
- Operates in a specialized segment of the medical technology industry.
What Investors Ask About Caliber Imaging & Diagnostics, Inc. (LCDX) — Healthcare
What does Caliber Imaging & Diagnostics, Inc. do?
Caliber Imaging & Diagnostics, Inc. is a U.S.-based medical technology firm specializing in advanced imaging solutions that enable the visualization of living tissue at a cellular resolution. Their core offerings include the VivaScope 1500, a reflectance confocal imaging system, and the VivaScope 3000, a handheld in vivo reflectance confocal microscope primarily for dermatological imaging. Complementing these hardware devices, the company provides VivaScan software for streamlined patient management and image analysis, and VivaNet, a digital telepathology system. These products collectively empower medical practitioners and scientists with detailed diagnostic capabilities for various applications.
What are the key growth opportunities for LCDX in healthcare?
Caliber Imaging & Diagnostics, Inc. has several growth opportunities within the healthcare sector. One key area is the expansion of its cellular-resolution imaging technology into new diagnostic applications beyond its current focus, such as oncology or pathology, leveraging the growing demand for precise early diagnosis. Another opportunity lies in geographic market penetration, extending its reach beyond the U.S. into international markets with increasing healthcare investments. Furthermore, integrating advanced AI and machine learning into its VivaScan and VivaNet software platforms could enhance diagnostic accuracy and efficiency, creating new value propositions and potential recurring revenue streams.
What are the main risks for LCDX?
Caliber Imaging & Diagnostics, Inc. faces several significant risks. Financially, the company exhibits substantial unprofitability with a -164.0% profit margin, raising concerns about its long-term sustainability and operational efficiency. Its 'OTC Other' listing and 5K market capitalization contribute to extremely limited liquidity and transparency, making it challenging for investors to trade shares and for the company to attract institutional funding. There is an ongoing risk of intense competition from larger medical device firms with greater resources. Additionally, the company must continuously navigate complex and evolving regulatory landscapes for medical devices, which can be costly and time-consuming.
What revenue streams does Caliber Imaging & Diagnostics, Inc. have in healthcare?
Caliber Imaging & Diagnostics, Inc. primarily generates revenue through the sale of its advanced medical imaging hardware and associated software solutions. This includes the direct sale of its VivaScope 1500 reflectance confocal imaging systems and the VivaScope 3000 handheld in vivo reflectance confocal microscopes to medical practitioners, dermatologists, and research institutions. Additionally, the company derives revenue from its proprietary software platforms, VivaScan and VivaNet. These software solutions, which streamline patient scheduling, imaging, review, and telepathology, likely contribute through licensing fees, subscriptions, or bundled sales with their hardware. Revenue may also come from service contracts and support for their installed base of imaging systems.
How does Caliber Imaging & Diagnostics, Inc. address diagnostic needs in dermatology?
Caliber Imaging & Diagnostics, Inc. specifically addresses dermatological diagnostic needs through its VivaScope 3000, a handheld in vivo reflectance confocal microscope. This device is tailored for dermatological imaging, allowing practitioners to visualize skin tissue at a cellular resolution directly on the patient, without the need for invasive biopsies in many cases. This capability provides detailed insights into cellular architecture, aiding in the early detection and diagnosis of various skin conditions, including potential malignancies. By offering non-invasive, high-resolution imaging, the VivaScope 3000 enhances diagnostic accuracy and efficiency for dermatologists, improving patient care pathways.
What are the key factors to evaluate for LCDX?
Caliber Imaging & Diagnostics, Inc. (LCDX) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does LCDX data refresh on this page?
LCDX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LCDX's recent stock price performance?
Caliber Imaging & Diagnostics, Inc. (LCDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary advanced imaging technology for cellular-resolution tissue visualization. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Specific market sizes and timelines for growth opportunities are inferred based on general industry trends due to lack of explicit data.
- Detailed CEO background and track record beyond basic information are not available in the provided sources.
- Competitor information (FMP PEER TICKERS) was not provided, so the 'competitors' array is empty.
- The 'tenureYears' field for the CEO is null as the start date was not provided.
- The 'disclosureLevel' for OTC analysis is 'Unknown' as stated in the source data.